New research finds that enzyme is absent in Crohn's disease sufferers

September 18, 2013, Royal Veterinary College

Royal Veterinary College researcher Dr David Bishop-Bailey, alongside collaborators from University College London, Queen Mary University London, the University of Umeå and the National Institute of Environmental Health Sciences / National Institutes of Health have discovered that an enzyme which helps immune cells to clear infections caused by bacteria appears to be absent in patients suffering from Crohn's disease.

It is hoped that the findings, which have been published in the journal PLoS ONE, will open up a new pathway to investigate for therapeutic intervention in Crohn's disease, a form of Inflammatory Bowel Disease which affects thousands of people in the UK.

Crohn's Disease is a condition that causes inflammation of the digestive system, also known as the or gut and is associated with an inability to clear infections such as those caused by bacteria. Crohn's is sometimes described as a chronic condition, meaning that it is ongoing and usually lifelong.

Dr Bishop-Bailey and his colleagues used human cell lines and cells from volunteers and Crohn's disease patients to investigate the enzyme CYP2J2, as its role in sensing and clearing bacteria is currently not known and its regulation in human inflammatory diseases is poorly understood.

During their investigation they discovered that CYP2J2 helps immune cells take up bacteria to remove them and that this enzyme appears to be absent in stimulated from Crohn's disease patients.

Dr Bishop-Bailey said: "We hope that this research may open up new therapeutic avenues for Crohn's disease and lead to new tests into whether mimicking or bypassing CYP2J2 by giving its enzymatic products can lead to beneficial effects for the thousands who sufferer from this disease."

Explore further: Potential Crohn's treatment starts clinical trial

More information: Bystrom, J. et al. (2013) Inducible CYP2J2 and its product 11,12-EET promotes bacterial phagocytosis: a role for CYP2J2 deficiency in the pathogenesis of Crohn's Disease? PLoS One, 8 (9): e75107. dx.doi.org/10.1371/journal.pone.0075107

Related Stories

Potential Crohn's treatment starts clinical trial

September 17, 2013
UCF College of Medicine professor Dr. Saleh Naser soon will participate in a clinical trial to test whether a new antibiotic therapy acquired by RedHill Biopharma can be used to treat Crohn's disease patients.

Females fend off gut diseases

June 11, 2013
At least among mice, females have innate protection from certain digestive conditions, according to a new Michigan State University study.

How does fibrosis occur in Crohn's disease?

January 30, 2013
New research has shown that a protein, known as IL-13, could be the key to the development of fibrosis in Crohn's disease. This breakthrough could help to advance new medicines to treat people suffering with the disease.

Two studies identify potential new drug for Crohn's disease and ulcerative colitis

August 21, 2013
Vedolizumab, a new intravenous antibody medication, has shown positive results for treating both Crohn's disease and ulcerative colitis, according to researchers at the University of California San Diego, School of Medicine. ...

Scientists uncover protective influence of Vitamin A against inflammatory bowel disease

June 5, 2013
Scientists at Trinity College Dublin have made novel discoveries around the protective influence of Vitamin A against the damaging immune responses that lead to inflammatory bowel disease. The research led by Professor of ...

Cell death protein could offer new anti-inflammatory drug target

September 5, 2013
Scientists in Melbourne, Australia, have revealed the structure of a protein that is essential for triggering a form of programmed cell death, making possible the development of new drugs to treat chronic inflammatory diseases ...

Recommended for you

Building better tiny kidneys to test drugs and help people avoid dialysis

February 16, 2018
A free online kidney atlas built by USC researchers empowers stem cell scientists everywhere to generate more human-like tiny kidneys for testing new drugs and creating renal replacement therapies.

Expanding Hepatitis C testing to all adults is cost-effective and improves outcomes

February 16, 2018
According to a new study, screening all adults for hepatitis C (HCV) is a cost-effective way to improve clinical outcomes of HCV and identify more infected people compared to current recommendations. Using a simulation model, ...

Study suggests expanded range for emerging tick-borne disease

February 16, 2018
Human cases of Borrelia miyamotoi, a tick-borne infection with some similarities to Lyme disease, were discovered in the eastern United States less than a decade ago. Now new research led by the Yale School of Public Health ...

Flu shot only 36 percent effective, making bad year worse (Update)

February 15, 2018
The flu vaccine is doing a poor job protecting older Americans and others against the bug that's causing most illnesses.

IFN-mediated immunity to influenza A virus infection influenced by RIPK3 protein

February 15, 2018
Each year, influenza kills half a million people globally with the elderly and very young most often the victims. In fact, the Centers for Disease Control and Prevention reported 37 children have died in the United States ...

A new class of drug to treat herpes simplex virus-1 infection

February 14, 2018
For patients with the herpes simplex-1 virus (HSV-1), there are just a handful of drugs available to treat the painful condition that can affect the eyes, mouth and genitals.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.